Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
APMIS · 2025-01 · 133 (1)
DOI: 10.1111/apm.13515 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift APMIS, online erschienen am 14.01.2025. Verfasst von Sandeep und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibody Specificity, Antigens, Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Science and Engineering Research Board (SERB), New Delhi, National Institute of Phrarmaceutical Education and Research, SAS Nagar, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Development of antibodies for clinical use is a complex process involving numerous aspects, with antigen specificity being the most important. Initially, polyclonal antibodies, that can recognize multiple specific and nonspecific antigens (polyreactive), were developed and were very effective in the treatments. Later on, the polyspecificity/polyreactivity of these polyclonal antibodies (binding to multiple antigens) raised concerns about therapeutic efficacy because of their nonspecific interactions and challenges, such as development of immune complexes, batch‐to‐batch variability. This highlighted the need for more targeted approaches. It was resolved by the marked invention of hybridoma technology in 1975 which resulted in the revolution in the antibody development field by offering monoclonal monospecific antibodies (bind single antigen). However, their limited application in complex pathologies sparked a paradigm shift, leading to the resurgence of polyspecific antibodies in the form of monoclonal polyspecific antibodies (Polybodies), which bind multiple antigens, but specifically. Till today, 14 Polybodies are approved for clinical use. This fluctuation in antigen specificity is directing the evolution of engineered antibodies that are going to drive the biopharmaceutical sector in the coming years. Through this write‐up, we assert the fluctuating nature of antigen specificity during the antibody development and how it will be crucial for advancing biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India.
ORCID-Profile: Abhay H Pande
Förderung
- Science and Engineering Research Board (SERB), New Delhi
- National Institute of Phrarmaceutical Education and Research, SAS Nagar
- Department of Biotechnology, Ministry of Science and Technology, India
- Science and Engineering Research Board
Zitieren
APA
Sandeep, Shinde, S. H., & Pande, A. H. (2025). Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?. APMIS, 133(1). https://doi.org/10.1111/apm.13515
Vancouver
Sandeep, Shinde SH, Pande AH. Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?. APMIS. 2025;133(1). doi:10.1111/apm.13515
BibTeX
@article{Sandeep2025,
author = {Sandeep and Shinde, Suraj H and Pande, Abhay H},
title = {Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?},
journal = {APMIS},
year = {2025},
volume = {133},
number = {1},
doi = {10.1111/apm.13515}
}
EUVIMED